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In plasmodia, the dihydrofolate reductase (DHFR) enzyme is the target of the pyrimethamine component of
sulfadoxine-pyrimethamine (S/P). Plasmodium vivax infections are not treated intentionally with antifolates.
However, outside Africa, coinfections with Plasmodium falciparum and P. vivax are common, and P. vivax in-
fections are often exposed to S/P. Cloning of the P. vivax dhfr gene has allowed molecular comparisons of dhfr
alleles from different regions. Examination of the dhfr locus from a few locations has identified a very diverse
set of alleles and showed that mutant alleles of the vivax dhfr gene are prevalent in Southeast Asia where S/P
has been used extensively. We have surveyed patient isolates from six locations in Indonesia and two locations
in Papua New Guinea. We sequenced P. vivax dhfr alleles from 114 patient samples and identified 24 different
alleles that differed from the wild type by synonymous and nonsynonymous point mutations, insertions, or
deletions. Most importantly, five alleles that carried four or more nonsynonymous mutations were identified.
Only one of these highly mutant alleles had been previously observed, and all carried the 57L and 117T
mutations. P. vivax cannot be cultured continuously, so we used a yeast assay system to determine in vitro
sensitivity to pyrimethamine for a subset of the alleles. Alleles with four nonsynonymous mutations conferred
very high levels of resistance to pyrimethamine. This study expands significantly the total number of novel dhfr
alleles now identified from P. vivax and provides a foundation for understanding how antifolate resistance
arises and spreads in natural P. vivax populations.
Plasmodium vivax causes a severe and debilitating febrile
illness. This mosquito-borne parasite infects an estimated 80
million people each year and is a prevalent cause of malaria
outside sub-Saharan Africa (39). Unfortunately, P. vivax can-
not be maintained in continuous culture, so despite its preva-
lence, the study of vivax has lagged markedly behind that of
Plasmodium falciparum. This difference is particularly true
with respect to the genetics and epidemiology of drug resis-
tance in P. vivax. Chloroquine has been the first-line antima-
larial treatment in most areas of endemicity, but resistance to
this drug has virtually eliminated its usefulness against P. fal-
ciparum (61, 63, 65) and chloroquine resistance has now been
observed with P. vivax as well (1, 21, 34, 45, 52, 55, 58, 59).
Fansidar, a fixed combination of sulfadoxine and pyrimeth-
amine (S/P), is most often the alternative chosen when chlo-
roquine-resistant P. falciparum parasites render chloroquine
ineffective (4). However, S/P has not been recommended for
primary therapy of vivax malaria due to the poor clinical effi-
cacy reported when the drug was introduced in the 1950s (13,
14, 26, 49, 64, 68).
In both P. falciparum and P. vivax, the dihydrofolate reduc-
tase (DHFR, E.C. 1.5.1.3) enzyme is the therapeutic target of
the pyrimethamine component of S/P (12, 18, 23, 26, 27, 43, 44,
60). A combination of in vitro analysis of cultured parasites
and molecular analysis of field isolates has allowed a clear
definition of the genetic basis for pyrimethamine resistance in
P. falciparum (reviewed in references 25 and 53). A point
mutation from serine to asparagine at codon 108 of the falci-
parum dhfr gene increases resistance slightly, and the subse-
quent addition of changes at combinations of 6 codons (A16V,
C50R, N51I, C59R, S108N, and I164L) increases the resistance
markedly (8, 47, 48). The simplicity of this picture is remark-
able; the mutations that contribute to pyrimethamine resis-
tance appear to be the same worldwide, synonymous substitu-
tions are very rarely observed, and only one insertion has ever
been reported (7). These patterns support the idea that the
present P. falciparum populations have evolved recently from a
few founders and spread virtually worldwide from these foci,
probably influenced by the strong selection pressure of drug
treatment (6, 42, 51, 67).
Limited studies to date have demonstrated that there is a far
higher level of overall genetic diversity in the P. vivax popula-
tion than one observes in the P. falciparum population (9, 16,
29, 41). This difference is likely to be important to the evolu-
tion of drug resistance. Vivax infections are not often treated
intentionally with antifolates like pyrimethamine, yet coinfec-
tions with P. falciparum and P. vivax are common in southern
and Southeast Asia and South America (36, 38, 57). As a
result, P. vivax organisms are often exposed to S/P because
fevers are presumptively treated or mixed infections are mis-
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diagnosed. Because P. vivax cannot be continuously cultured,
in vitro determination of drug sensitivity is extremely difficult.
However, cloning of the dhfr gene from P. vivax (11) has
allowed molecular comparisons of alleles from different re-
gions. Examination of the dhfr locus from only a few locations
has already yielded more unique dhfr alleles in vivax popula-
tions than the far more extensive examination of P. falciparum
has demonstrated (12, 23, 24, 26, 27, 60). In particular, these
studies showed that mutant alleles of the vivax dhfr gene are
prevalent in Southeast Asia in areas where there is a long
history of extensive S/P use. In contrast, wild-type vivax dhfr
has been found more commonly in regions with limited or no
historical use of S/P (12, 26, 27, 60).
So far, these studies have not been sufficient to define the
overall patterns of the genetic diversity in P. vivax, but two
previous reports have identified different characteristic subsets
of vivax dhfr alleles in Central Java and Papua (23, 60), and
another distinct subset has been reported in Thailand (27). In
this study, we surveyed vivax dhfr alleles at six locations in the
Indonesian archipelago and two locations in Papua New
Guinea (PNG). We sequenced alleles from 114 patient sam-
ples and used a Saccharomyces cerevisiae assay system to de-
termine the relative in vitro sensitivity to pyrimethamine for a
subset of the alleles.
This study adds significantly to the number of unique dhfr
alleles identified in previous data sets. The identification of
novel pyrimethamine-resistant vivax dhfr alleles and character-
ization of their distribution in the Indonesian archipelago is
the first step toward understanding how antifolate resistance
arises and spreads in natural P. vivax populations.
MATERIALS AND METHODS
Patient samples. The Indonesian isolates evaluated in this study are comprised
of subsets of samples from clinical studies conducted in the Armopa region of
northeastern Papua (1996 to 1999) (2, 31), Purworejo in southern Central Java
(2000) (3, 32), Legundi Island in South Lampung, Sumatra (July, 2000) (33), Gag
Island, Papua Province (April 1997) (19), Ketapang, West Kalimantan (July
1996) (20), and Maumere, East Flores (April 1996). In addition, a single sample
was available from Laut Island, South Kalimantan (June 2002). The isolates from
PNG evaluated in this study are a subset of samples from a clinical study
conducted in the Wosera (1998 to 1999) and Liksul (2000) areas. This study has
also been described in detail elsewhere (37). All subjects had slide- and PCR-
proven infection by P. vivax. None of the subjects received S/P therapy; infections
were treated with chloroquine or another antimalarial drug or combination, as
per the protocol of each study. The work with Indonesian subjects in this study
was reviewed (Department of Defense protocol no. 30820, 30839, and 30833)
and approved by U.S. Navy and Indonesian institutional review boards. All
Indonesian subjects provided written informed consent to participate in the study
in accordance with U.S. Navy regulations governing the use of human subjects of
medical research (SECNAVINST 3900.39C and BUMEDINST 3900.6B.). All
Papuan subjects provided informed consent, and the samples from PNG were
analyzed with the permission of the PNG Medical Research Advisory Committee
(MRAC no. 02.14).
Cloning and sequencing of dhfr. Genomic P. vivax DNA from the Indonesian
samples was extracted from dried blood blots on filter paper by using the blood
blot DNA extraction protocol from a commercial kit (QIAamp DNA mini kit;
QIAGEN). The samples from PNG were prepared at the time of collection from
whole blood by using QIAamp 96 spin blood kits (37). The dhfr gene was then
amplified by PCR in a 100-l reaction mixture, with 2 l of Taq polymerase
(Promega), 10 l of 10 PCR buffer, 8 l of 25 mM MgCl2, 1 l of each 10 M
primer, 1 l of 10 mM deoxynucleoside triphosphates, 10 l of template DNA,
and 67 l of PCR H2O. The primers used have been described previously (24).
The 5 end of each primer is complementary to the sequence of the shuttle
plasmid at the desired insertion position to facilitate homologous recombination
in yeast (7, 54). The cycling parameters were as follows: (i) initial denaturation
for 3 min at 94°C, followed by 5 cycles of denaturation at 94°C for 1 min,
annealing at 60°C for 1 min, and extension at 72°C for 1 min; (ii) 5 cycles of
denaturation at 94°C for 1 min, annealing at 55°C for 1 min, and extension at
72°C for 1 min; and (iii) 20 cycles of denaturation at 94°C for 1 min, annealing
at 50°C for 1 min, and extension at 72°C for 1 min.
The S. cerevisiae yeast strain used lacks endogenous DHFR activity and has
been described previously (66). Yeast cells were transformed by using a high-
efficiency lithium acetate protocol (28) and were then plated onto medium
lacking tryptophan, to select for the plasmid, and dTMP, to select for functional
DHFR activity. Escherichia coli strain DH5 was used for propagation and
preparation of the shuttle plasmid from the transformed yeast. The plasmid was
isolated and purified from the bacteria by using a commercial kit (QIAprep spin
miniprep kit; QIAGEN). Sequencing was conducted via fluorescent dye chem-
istry (MegaBACE; Amersham Pharmacia Biotech) and analyzed with Se-
quencher software (Gene Codes Corporation) and the ClustalW multiple-se-
quence alignment program in SDSC Biology Workbench, version 3.2. At least
two isolates were sequenced from each patient sample to check for mixed
genotypes; if the two were not in agreement, additional isolates were sequenced
to verify the mixed genotype. If a particular allele was not observed again after
10 isolates from that sample were sequenced, it was assumed to be a PCR artifact
and discounted from subsequent analysis.
In vitro susceptibility classification. The 50% inhibitory concentration (IC50)
assays were performed as previously described to obtain quantitative measures of
drug sensitivity (23). The growth of the yeast in this assay depends upon the
antifolate resistance of the dhfr allele expressed. An IC50 is defined as the
concentration of drug at which the growth of the yeast culture is inhibited by 50%
relative to the untreated control. Yeast cells transformed with dhfr from P. vivax
were grown overnight in a 96-well culture dish in complete medium (yeast
extract-peptone-dextrose broth) lacking supplemental dTMP. The growth of the
yeast cells in each well was assessed by spectrophotometry after approximately
24 h of incubation at 30°C, the amount of time required for the untreated control
yeast cells to reach mid-log phase. The average reading of six wells for each allele
at each drug concentration was then used to plot the percent growth relative to
the control. The average reading of 12 wells was used for the control yeast cells.
The numerical IC50 was calculated from the slope and intercept of the line
defined by the two averaged data points that bracket 50% relative growth.
Comparisons of the IC50s of the mutant alleles to the wild-type allele were used
to assess the relative drug resistance level of each allele. IC50 assays were
performed at least twice for each allele to determine the standard deviation and
to ensure reproducibility.
Nucleotide sequence accession number. The complete sequence of the alleles
identified has been submitted to GenBank and assigned accession numbers
AY772063 to AY772087.
RESULTS
P. vivax dhfr alleles identified in Indonesia and PNG. In this
study, we examined samples from eight geographic locations,
including six sites in Indonesia and two sites in PNG, and
identified 137 dhfr alleles from 114 patients. Figure 1 shows the
approximate position of each sampling location; the pie charts
indicate the proportion of the alleles from each location that
carried particular numbers of mutations. The genotypes of all
alleles that we identified are listed in Table 1. The reference
sequence was the wild-type Burma-6 sequence provided in
GenBank (accession no. AJ222633), and we considered inser-
tions, deletions, and synonymous or nonsynonymous point mu-
tations. Each unique nucleotide sequence was counted as a
separate allele. The exact sequence of each allele has been
submitted to GenBank (accession numbers AY772063 to
AY772087).
Our goal was to identify a broad range of dhfr alleles. We
amplified and cloned the dhfr allele(s) from each patient sam-
ple and sequenced at least two independent clones to identify
mixed infections and eliminate any mutations that may have
been introduced by polymerase error. If the first two sequences
were not in agreement, additional isolates were sequenced to
verify each allele. If a particular allele was not observed again
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after 10 isolates from that sample were sequenced, it was
assumed to be a PCR artifact and discounted from subsequent
analysis. Polyclonal P. vivax infections were common in this
sample set, and we have not exhaustively identified all alleles in
each patient sample. As a result, our survey does not measure
either the population frequency of any given allele or the
proportion of each allele in a polyclonal infection. Our data are
indicative only of general trends and patterns in Indonesia and
PNG, and the allele frequencies reported are specific to the set
of samples analyzed in our study.
Commonly observed alleles. The most common allele in this
data set matched the wild-type dhfr sequence (37.2%), with no
point mutations, insertions, or deletions. Most of the wild-type
alleles came from three study sites: Gag, Indonesia; Flores,
Indonesia; and the Wosera, PNG. Two alleles with point mu-
tations resulting in an arginine at position 58 and an asparagine
at position 117 (58R/117N) accounted for another quarter of
the isolates (24.8%). One of these double-mutant alleles has a
deletion of codons 98 to 103 and was found in Central Java,
Indonesia, and Legundi, Indonesia. The other 58R/117N allele
has no insertions or deletions and was found in four of the six
Indonesian study sites. Two alleles with four point mutations,
57L/58R/61M/117T and 57L/111L/117T/173F, were also com-
mon, accounting for 7.3 and 5.1% of the alleles, respectively.
The 57L/58R/61M/117T allele was primarily found in Papua,
Indonesia, but was also isolated from a single sample from
South Kalimantan and a polyclonal sample from West Kali-
mantan. The 57L/111L/117T/173F allele was the most common
FIG. 1. Map of locations from which samples were derived. All locations had numerous samples, except the southernmost Kalimantan site
which had only a single patient sample. That location is indicated by a dot only, and the sample was included with the West Kalimantan samples
for analysis. The pie charts show the proportions of alleles that showed a particular number of point mutations. The darkest color indicates 4 or
more nonsynonymous mutations, and the progressively lighter shades show 3, 2, or 1 mutation; white indicates the wild type.
TABLE 1. Unique dhfr allele sequences observed
No. of
isolates
% of
total
Change(s) in sequence from wild type
No. of
locationsMutation(s) Indel
Nonsynonymous Synonymous
51 37.2 None None None 7
18 13.1 58R/117N None None 4
16 11.7 58R/117N None Deletion A 2
10 7.3 57L/58R/61M/117T None None 2
7 5.1 57L/111L/117T/173F None None 1
6 4.4 57L/58R 38GGC None 1
5 3.6 58R/117N/199V None None 2
2 1.5 58R None None 1
2 1.5 None 215CGA None 1
2 1.5 None None Insertion A 2
2 1.5 None None Insertion B 1
2 1.5 None None Deletion B 2
2 1.5 None None Deletion A 1
1 0.7 None None Insertion C 1
1 0.7 None None Insertion D 1
1 0.7 199V None None 1
1 0.7 117N None Insertion C 1
1 0.7 57L/58R None Insertion A 1
1 0.7 58R/117N 196ATA None 1
1 0.7 58R/117N/99S None None 1
1 0.7 58R/61M/117T None None 1
1 0.7 57L/58R/117T None None 1
1 0.7 15S/57L/117T/173F None None 1
1 0.7 57L/111L*/117T/173Fa None None 1
1 0.7 49R/57L/58R/61M/117T None None 1
a The asterisk denotes CTG at codon 111 instead of TTG.
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allele found in Ketapang, West Kalimantan, but also was ob-
served in a single sample from Java. A 57L/58R allele with a
silent mutation at position 38 was common in the Liksul, PNG
study site and accounted for 4.4% of all alleles identified in this
study. The 58R/117N/199V allele, found primarily in the Papua
study site, accounted for 3.6% of alleles. Thus, this commonly
observed set of 7 alleles accounted for approximately 80% of
the alleles identified.
Less commonly observed alleles. An additional 18 alleles
were found only once or twice, for a grand total of 25 unique
alleles. Fifteen of these alleles have not been previously iden-
tified in the published literature; only the deletion B, 58R, and
57L/58R/117T alleles have been previously identified (11, 23).
Two of the rare alleles were defined by the presence of a
synonymous point mutation: wild type with CGA at codon 215
and 58R/117N with ATA at codon 196. There were three rare
alleles with three nonsynonymous point mutations (58R/117N/
99S, 58R/61M/117T, and 57L/58R/117T), two alleles with four
nonsynonymous point mutations (15S/57L/117T/173F and 57L/
111L*/117T/173F), and one allele with five nonsynonymous
point mutations (49R/57L/58R/61M/117T).
Insertions and deletions. We identified several alleles de-
fined by the presence of an insertion or deletion. Details of
the insertions and deletions (indels) are given in Table 2. All of
the indels were localized to a central GGDN repeat region of
the gene that is thought to be nonessential for substrate bind-
ing and which is missing entirely from the P. falciparum dhfr
coding sequence (50). Furthermore, all of the indels involved
18 bp of sequence, except for one 36-bp insertion found in an
allele from the Wosera. The exact nucleotide coordinates of
the indels could not always be determined due to the repetitive
nature of the GGDN repeat region but was estimated based on
previous reports in the literature.
Codon usage. Some alleles that encoded identical polypep-
tides differed in their nucleotide sequences. For example, there
were two 57L/111L/117T/173F alleles, both found in Kaliman-
tan. The leucine at position 111 was encoded by CTG in one
allele and by TTG in the other, more common allele. Similarly,
the leucine at position 57 was encoded by CTC in the 57L/
58R/61M/117T allele and by TTG in the 57L/111L/117T/173F
and 57L/58R alleles. The arginine at position 58 was encoded
by AGA in the 57L/58R allele in Liksul and in the 58R and
58R/117N/199V alleles and by AGG in all other alleles. The
CGC codon for arginine at position 58 was not found in this
sample set nor was the TTA codon for leucine at position 57.
Geographic trends. Despite the fact that all of the study sites
are located in the same archipelago, most of the dhfr alleles
were found in only one or two of the study locations (Table 3).
Only the wild-type allele was found in a majority (7 of 8) of the
sites. The 58R/117N allele was found in 4 study sites, all in
Indonesia. Papua and Kalimantan were the only locations in
which the majority of the alleles had more than two nonsynon-
ymous point mutations (55.5 and 62.6%, respectively). The Wo-
sera, Gag, and Flores samples had primarily wild-type alleles.
Polyallelic samples. Multiple vivax dhfr alleles were identi-
fied in 18 (15.8%) of the 114 patient samples. This is a con-
servative estimate of the number of polyclonal infections, as it
is based on only one locus and the patient samples were not
exhaustively evaluated to identify all dhfr alleles present. The
majority of the patient samples from Legundi were of mixed
genotype; the Papua, Kalimantan, and Liksul study sites also
had more than one polyallelic sample. The largest number of
dhfr alleles found in any one sample was four, from a patient in
the West Kalimantan study site. Three alleles were found in
one patient sample from the Papua study site; only two differ-
ent alleles were found in the other polyallelic samples.
TABLE 2. Nucleotide sequences and coordinates of
insertions and deletions observeda
Insertion or
deletion Codons
No. of
bp Sequence
Insertion A 103, 104 18 ACACACGGTGGTGACAAC
Insertion B 103, 104 18 ACAAGCGGTGGTGACAAC
Insertion C 98, 99 18 AGCGGTGGTGACAACACA
Insertion D 98, 99 36 AGCGGTGGTGACAACACAC
ACGGTGGTGACGACACA
Deletion A 98–103 18 ACACACGGTGGTGACAAC
Deletion B 92–97 18 AACACAAGCGGTGGTGAC
a No examples of alleles with both an insertion and a deletion were identified.
TABLE 3. Geographic distribution of allelesa
Location No. (%)of alleles
Change(s) in sequence from wild type
Mutation(s)
Indel
Nonsynonymous Synonymous
Wosera 17 (89.5) None None None
1 (5.3) None None Insertion D
1 (5.3) 57L/58R None Insertion A
Liksul 12 (48.0) None None None
6 (24.0) 57L/58R 38GGC None
2 (8.0) 58R None None
2 (8.0) None 215CGA None
1 (4.0) None None Insertion A
1 (4.0) None None Deletion B
1 (4.0) 199V None None
Papua 8 (29.6) 57L/58R/61M/117T None None
7 (25.9) 58R/117N None None
4 (14.8) None None None
4 (14.8) 58R/117N/199V None None
1 (3.7) 117N None Insertion C
1 (3.7) 58R/61M/117T None None
1 (3.7) 57L/58R/117T None None
1 (3.7) 49R/57L/58R/61M/117T None None
Gag 5 (62.5) None None None
2 (25.0) None None Insertion B
1 (12.5) 58R/117N 196ATA None
Legundi 5 (41.7) 58R/117N None None
5 (41.7) 58R/117N None Deletion A
1 (8.3) None None Insertion C
1 (8.3) None None Deletion B
Central Java 11 (50.0) 58R/117N None Deletion A
5 (22.7) 58R/117N None None
2 (9.1) None None None
1 (4.5) None None Insertion A
1 (4.5) 58R/117N/99S None None
1 (4.5) 15S/57L/117T/173F None None
1 (4.5) 57L/111L/117T/173F None None
Flores Kali-
mantan
8 (100) None None None
7 (43.8) 57L/111L/117T/173F None None
3 (18.8) None None None
2 (12.5) None None Deletion A
2 (12.5) 57L/58R/61M/117T* None None
1 (6.3) 58R/117N None None
1 (6.3) 58R/117N/199V None None
a The starred allele derived from a single sample from South Kalimantan and
a sample from Ketapang, West Kalimantan.
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In vitro resistance to pyrimethamine. We have established
an expression system for the P. vivax dhfr gene in yeast cells
that lack endogenous DHFR activity. For alleles of P. falcipa-
rum, the in vitro sensitivity of these engineered yeast lines to
antifolate drugs reflects the sensitivity of the parasite from
which the dhfr allele was isolated (17, 22, 66). To define the
range of pyrimethamine sensitivity represented in these
P. vivax alleles, we created yeast lines dependent upon each of
7 alleles: the wild type and two double-, two triple-, and two
quadruple-mutant alleles. These were grown in 0 to 500 M
pyrimethamine, and the concentration of drug required to
inhibit yeast growth by 50% (the IC50) was measured. Figure 2
shows representative data. The IC50 value of the yeast depen-
dent upon the wild-type allele was approximately 1 M. The
57L/58R double mutant was only about sevenfold more resis-
tant than the wild type. The 58R/117N double-mutant allele
and the two triple-mutant alleles all showed similar, higher
levels of resistance, about 200- to 300-fold higher than that of
the wild-type allele. Finally, both of the quadruple-mutant al-
leles tested were highly pyrimethamine resistant; the growth of
these strains of yeast was unaffected by up to 500 M, the max-
imum concentration of pyrimethamine that can be tested in the
assay. Thus, an IC50 could not be measured for these alleles.
DISCUSSION
The enormous diversity of the P. vivax dhfr alleles identified
in this relatively small sample set is in striking contrast to the
very limited degree of polymorphism that is observed in dhfr
alleles from P. falciparum. This is particularly interesting con-
sidering that the antifolate drug treatments that drive the se-
lection of mutated alleles are presumably the same in this
region, where P. falciparum and P. vivax are sympatric and co-
infections and simultaneous treatment are common. The rea-
sons for the contrast cannot be clearly defined, but there are
numerous biological, demographic, and epidemiologic differ-
ences between the two species. For example, the repeated
relapses of hypnozoites from P. vivax in patients may be one
element that contributes to its genetic diversity. It has also
been proposed that P. vivax has been a primate parasite for
much longer than P. falciparum and thus has had far longer to
accumulate polymorphisms (16). Certainly, differences in both
biological patterns and evolutionary history must play a role,
and whatever the origin of the diversity, it will complicate devel-
opment of both drug treatments and vaccines against P. vivax.
The samples in our set were taken from a variety of loca-
tions, and the patterns of allelic diversity varied enormously.
Several populations, like Gag Island and the Wosera region of
PNG, contained wild-type dhfr almost exclusively, whereas
samples from the Indonesian regions of Papua and Kalimantan
carried numerous different alleles, some with four or five mu-
tations that confer high levels of pyrimethamine resistance.
The small sample size does not allow one to draw definitive
conclusions about the patterns of gene flow, but the extent of
mixing of human populations and the history of antifolate drug
use have varied enormously among these sites. Both factors are
likely to have a profound effect on the diversity of each local
P. vivax population. Moreover, the biogeographically fragment-
ed populations of plants, animals, and humans in this island
archipelago have been noted as a fantastic source of genetic
diversity for more than a century (62), and the P. vivax popu-
lations certainly follow this pattern.
It is clear that areas where antifolate use has been intensive,
like Thailand and Indonesian Papua, show a higher prevalence
of alleles that carry more than two mutations and encode
DHFR enzymes that are more resistant to pyrimethamine (5,
24, 26, 27, 60). Treatment of mixed-species infections, the use
of pyrimethamine or S/P in suppressive treatment, and use of
S/P in presumptive treatment have all likely exerted selective
FIG. 2. Pyrimethamine sensitivity of yeast strains dependent upon P. vivax dhfr alleles. Yeast strains were grown in liquid culture with the
indicated concentrations of pyrimethamine, and growth relative to the same strain without pyrimethamine was measured after 24 h as described
in Materials and Methods.
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pressure on P. vivax dhfr in Indonesia. A massive effort at
suppressive treatment with pyrimethamine was attempted in
the 1950s in Papua (40) and was more recently undertaken
with S/P in the transmigrant camps in Papua and Kalimantan
(2, 20, 31). This is almost surely the reason for the high fre-
quency of quadruple-mutant alleles in these study sites. In
other areas, such as Java and Legundi, presumptive treatment
likely plays a dominant role. Inadvertent treatment of P. vivax
in mixed infections, where the P. vivax component is cryptic, is
also a well-documented phenomenon in the literature; it is
quite common for a P. vivax infection to follow a treated
P. falciparum infection by a few weeks or vice versa (35, 36, 49,
56, 57). Unfortunately, teasing apart the various mechanisms
behind the selection of the resistant alleles in each study site
was beyond the scope of this paper, as there is not enough
baseline information for these study sites. The presence of
highly resistant P. vivax dhfr alleles in areas where pyrimeth-
amine and S/P use have been particularly intensive provides
evidence that drug measures against P. falciparum malaria
exert correspondingly significant pressures against P. vivax,
whether or not this is intentional
Perusal of the larger data set also demonstrates that there
are two main branches of the selection process, based on dhfr
sequence. Those alleles that carry the 117N mutation are com-
mon but do not confer exceedingly high levels of pyrimeth-
amine resistance. However, the alternate 117T mutation is al-
ways found among the highly pyrimethamine-resistant alleles
with four or five nonsynonymous point mutations. This appar-
ent dichotomy has some practical consequences. For example,
the common 58R/117N allele apparently cannot accommodate
an additional mutation at position 57. This particular triple-
mutant allele has not been observed in field isolates, and it
failed to complement the DHFR-deficient yeast line when it
was created in the lab. Thus, the 58R/117N allele, while mod-
erately resistant to pyrimethamine, may represent a dead end
with respect to the evolution of high levels of drug resistance.
Interestingly, alleles with the 117N mutation do not demon-
strate significantly increased resistance to the experimental
DHFR inhibitor WR99210 (24). In contrast, all five highly py-
rimethamine-resistant alleles identified in this study carried
both the 117T mutation and the 57L mutation. This pattern is
consistent with three highly pyrimethamine-resistant alleles re-
cently identified in Thailand (26). Thus, the presence of thre-
onine at position 117 rather than arginine seems to allow more
key mutations to accumulate without significant loss of enzyme
function, resulting in higher levels of resistance to pyrimeth-
amine. These alleles also show a moderate increase in resis-
tance to WR99210 (data not shown).
The combined data sets also allow correlations to be made
between the molecular analysis of the dhfr alleles and the
clinical effectiveness of S/P against P. vivax infections. A recent
study showed that Indonesian patients infected with P. vivax
that carried up to three mutations in dhfr were still responsive
to S/P treatment (23). In contrast, patients whose parasites
carried the 57L/61M/117T/173F allele were far more likely to
fail S/P treatment (23, 60). The presence of parasites with four
or five mutations in dhfr has also been associated with reduced
parasite clearance rates in Thailand (26). The novel quadruple
and quintuple mutant alleles identified in this study have not
been tested for their clinical relevance, but in the yeast assay,
the quadruple-mutant alleles all conferred comparably high
levels of pyrimethamine resistance (data not shown). Thus, the
evidence indicates that clinical resistance to S/P is not inherent,
as it has been previously assumed, but rather is associated with
point mutations in vivax dhfr.
A limited number of mutations in dhfr are commonly asso-
ciated with antifolate resistance in P. falciparum. This regular-
ity has allowed the development of relatively simple allele-
specific oligonucleotide PCR and hybridization methods, and
these have been productively employed in molecular surveil-
lance (10, 15). The extremely high level of diversity in P. vivax
dhfr alleles argues strongly against such focused approaches.
There are too many mutations that need to be identified,
requiring complete sequencing of the gene. The two-branch
structure of the mutation families suggests that a simple PCR-
based method that would identify the 117T mutation may be
helpful as a first step, since all of the alleles identified to date
that encode highly pyrimethamine-resistant enzymes contain
this change. Only alleles that carry the 117T mutation would
then need to be followed up with direct sequencing to confirm
the presence of other mutations associated with high levels of
S/P resistance.
For decades, it has been assumed that S/P is not effective
against P. vivax. However, our findings suggest that in areas
where the prevalence of dhfr quadruple- and quintuple-mu-
tants is low, a DHFR inhibitor could provide one component
of an effective combination treatment against the erythrocytic
stages of vivax malaria. One possible partner would be a sulfa
or sulfone, although based on the information currently avail-
able, one may need to search for a partner other than sulfa-
doxine or dapsone (30). The molecular studies of dhfr muta-
tions so far are not a useful guide for individual clinical
decisions; the relationship between parasites’ genotype and
outcome of chemotherapy is too complex (46). The molecular
data can, however, provide important information for deci-
sions on population-based drug use in a region. The paucity of
information on P. vivax underlines the need to extend molec-
ular analyses to other areas where P. vivax is common, e.g., the
Indian subcontinent, Central Asia, the Middle East, Ethiopia,
and South and Central America (39). Based on the small
amount of information gathered so far, highly mutated alleles
of dhfr may not yet be common in these regions and S/P may
still provide effective treatment for the asexual erythrocytic
stages of vivax in areas where chloroquine treatment failure
has been reported. However, history suggests that selection of
high-level resistance will be rapid. Therefore, any drug should
be introduced in combination with a partner having a different
pharmacokinetic mechanism to retard the selection or spread
of resistant alleles. Our data contribute to the small but grow-
ing body of evidence suggesting that antifolates can provide
one component in the design of such a combination (23, 60).
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